ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ATHX Athersys Inc

0.1018
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Athersys Inc NASDAQ:ATHX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.1018 0.101 0.104 0 01:00:00

Athersys to Host Second Quarter Financial Results Call

10/07/2017 3:00pm

GlobeNewswire Inc.


Athersys (NASDAQ:ATHX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Athersys Charts.

Athersys, Inc. (Nasdaq:ATHX) will release its second quarter 2017 financial results at approximately 4:00 PM Eastern Time on Wednesday, August 9, 2017, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:

DateAugust 9, 2017
Time4:30 p.m. (Eastern Time)
Telephone access: US and Canada(800) 273-1254
Telephone access: International(973) 638-3440
Access code51542352
Live webcastwww.athersys.com under Investors section

A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on August 23, 2017 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 51542352.

About Athersys

Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.

ATHX-G

Contact:

William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900
bjlehmann@athersys.com

David Schull
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
David.schull@russopartnersllc.com

Investor Contact:
Peter Vozzo
Westwicke Partners
(443) 213-0505 or (443) 377-4767 (mobile)
Peter.vozzo@westwicke.com

1 Year Athersys Chart

1 Year Athersys Chart

1 Month Athersys Chart

1 Month Athersys Chart

Your Recent History

Delayed Upgrade Clock